Keryx Biopharmaceuticals (KERX) Phase 3 Study of Zerenex Meets Primary Endpoint
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced highly statistically significant positive results From Phase 3 Study of Zerenex ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


